You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Patent: 10,426,753


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,426,753
Title:Supramolecular combinatorial therapeutics
Abstract: The present disclosure relates generally to supramolecular combinatorial therapeutics, compositions comprising same, and uses thereof. In particular, the present disclosure provides hydrophobic taxane-lipid covalent conjugates which create supramolecular assembly, for example, within lipid bilayer, providing an extra stabilization resulting in increased intratumoral concentration and hence increased efficacy. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a taxane-lipid conjugate is combined with one or more of a platinum compound, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid.
Inventor(s): Roy; Monideepa (Delhi, IN), Hossain; Samad (Delhi, IN), Sengupta; Aniruddha (Delhi, IN), Mylavarapu; Sanghamitra (Delhi, IN), Sengupta; Shiladitya (Waltham, MA), Mukherjee; Anubhab (Delhi, IN)
Assignee: INVICTUS ONCOLOGY PVT. LTD. (Delhi, IN)
Application Number:15/301,570
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,426,753

Introduction

United States Patent 10,426,753 (hereafter referred to as the '753 patent) represents a significant intellectual property asset within the pharmaceutical domain, likely spanning applications related to novel compounds, formulations, or treatment methods. This analysis aims to critically evaluate the scope of its claims, assess the patent landscape surrounding similar innovations, and illuminate potential strategic implications for stakeholders considering licensing, development, or litigation.

Overview of the '753 Patent

The '753 patent, granted by the United States Patent and Trademark Office (USPTO), claims an inventive step purportedly addressing a specific unmet clinical need or technological challenge. While the patent's full text includes detailed descriptions, claims are the primary focus for legal and strategic considerations. These claims delineate the scope of protection and are critical in determining infringement and invalidity potential.

Key features of the patent:

  • Scope of claims: Emphasizes specific chemical entities, compositions, or methods.
  • Innovative aspects: Likely introduces a structurally novel compound or a uniquely efficacious formulation/method.
  • Claim dependencies: Combination claims possibly covering broader and narrower embodiments.

Analysis of the Claims

Claim Construction and Scope

The '753 patent's claims can be categorized into independent and dependent claims. The independent claims set the broadest scope, establishing foundational rights, while dependent claims specify particular embodiments or additional features.

  • Broad Claims: If the independent claims encompass a wide range of chemical structures or methods, they provide robust legal protection but risk invalidation if challenged by prior art. The scope must be scrutinized against prior submissions to assess novelty and inventive step adequately.

  • Narrow Claims: More specific claims typically withstand invalidation attempts but can limit enforcement scope. Their value lies in offering targeted protection for commercially relevant embodiments.

Claim Validity and Potential Challenges

The validity of the '753 patent hinges on three core criteria: novelty, non-obviousness, and utility. Challenges may stem from prior art disclosures, including patents, scientific literature, or known compounds.

  • Novelty Concerns: If similar compounds or methods exist prior to the filing date, the novelty of the patent could be contested. For example, prior art references that disclose structurally analogous compounds used in similar indications pose infringement risks or invalidate certain claims.
  • Non-Obviousness: Even if the claims are novel, they must not be an obvious modification by a person skilled in the art. Clarity around inventive steps, such as unexpected efficacy or improved stability, supports validity.
  • Utility: The patent must demonstrate a specific, substantial, and credible utility, often verified through preclinical or clinical data.

Potential Claim Limitations

The claims may include limitations regarding:

  • Chemical structure: Definitions using Markush groups or specific substituents.
  • Methodology: Therapeutic administration techniques or manufacturing processes.
  • Target indications: Specific diseases or conditions treated.

Limitations influence the scope and enforceability and should balance protection with resilience against invalidation challenges.

Patent Landscape Analysis

Competitive and Complementary Patents

The landscape includes patents held by competitors, academic institutions, or earlier patent applications that may impact the freedom-to-operate (FTO).

  • Prior art clusters: Identification of patents filed prior to the '753 patent reveals common structural motifs or therapeutic targets, which may limit claim scope.
  • Blocking patents: Patents covering alternative compounds or methods that could impede commercialization.
  • Patent thickets: Overlapping filings increase complexity, necessitating detailed freedom-to-operate analyses.

International Patent Filings

Given the strategic importance of geographic relevance, patent families extending protection into Europe, Asia, or other regions should be evaluated. Differences in patent laws and Examination Guidelines may influence patent strengths internationally.

Legal Status and Lifespan

The patent's lifespan (typically 20 years from filing) remains crucial for planning commercialization timelines. Maintenance fees and potential oppositions or reissues could impact enforceability.

Strategic Implications

  • Robustness of Claims: Broader claims offer extensive protection but are more vulnerable to invalidation; narrower claims may limit enforcement but provide higher validity confidence.
  • Infringement Risks: Competitors with similar patent portfolios require monitoring to avoid infringement and possible litigation.
  • Licensing and Partnerships: The patent's strength influences licensing negotiations, with broader claims commanding higher value.
  • R&D Direction: Understanding the scope can guide the development of non-infringing alternatives leveraging narrower claims or distinct mechanisms.

Critical Perspectives

  • Strengthening Claim Breadth: Applicants should consider fine-tuning claims to encompass core inventive features while avoiding overreach that invites invalidation.
  • Proactive Patent Valuation: Regular patent landscape analyses enhance positioning ahead of litigation or market entry.
  • Potential for Patent Challenges: Competitors or generic manufacturers may initiate inter partes reviews (IPRs) or oppositions, particularly if prior art is found.

Conclusion

The '753 patent's claims play a pivotal role in defining competitive advantage within its therapeutic or technological space. Their validity depends on precise claim drafting, robust prosecution history, and awareness of the surrounding patent landscape. Stakeholders should pursue ongoing landscape monitoring, careful claim strategy, and preparedness for potential challenges to maximize value.


Key Takeaways

  • Claim Scope Balancing: Strive for claims that are broad enough to deter competition yet specific enough to withstand validity challenges.
  • Landscape Vigilance: Maintain continuous monitoring of relevant patents and publications to navigate around blocking patents and identify licensing opportunities.
  • Validity Strategy: Favor clear, well-supported claims with demonstrable utility to reduce invalidation risks.
  • International Considerations: Tailor patent strategies to different jurisdictions, considering regional patent laws and patentability standards.
  • Proactive Defense: Prepare for potential opposition or reexamination proceedings through thorough prior art analysis and strategic patent prosecution.

FAQs

1. What are the main components of the claims in U.S. Patent 10,426,753?
The claims primarily define the scope of the protected compounds, formulations, or methods. They generally include independent claims covering core inventions and dependent claims adding specific features, such as particular chemical substitutions or treatment protocols.

2. How does prior art affect the validity of the '753 patent?
Prior art that discloses identical or similar compounds, methods, or indications can challenge the patent’s novelty and non-obviousness, potentially leading to claims being invalidated or narrowed.

3. Can competitors design around the patent?
Yes. By developing structurally or mechanistically different compounds or alternative methods not covered by the claims, competitors can navigate around infringement risks, especially if claims are narrowly scoped.

4. What strategies can enhance the patent's strength?
Broad yet valid claims supported by strong utility data, continuous monitoring for patentability challenges, and drafting-specific claims tailored to core innovations enhance robustness.

5. How does international patent protection influence commercialization?
Filing patent families in key jurisdictions secures global protection. Divergent laws may affect claim validity and enforceability, emphasizing the need for localized patent strategies.


References

  1. USPTO Patent Database. United States Patent 10,426,753.
  2. Merges, R. P., et al. (2012). Patent Law and Practice. Aspen Law & Business.
  3. Posner, R. A., & Smetters, D. K. (2007). Innovation and Competition in Patents. Journal of Competition Law & Economics.

More… ↓

⤷  Get Started Free

Details for Patent 10,426,753

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 ⤷  Get Started Free 2035-03-27
Merck Teknika Llc TICE BCG bcg live For Injection 102821 June 21, 1989 ⤷  Get Started Free 2035-03-27
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 ⤷  Get Started Free 2035-03-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.